Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Simcere Pharmaceutical Group Limited ( (HK:2096) ) has issued an announcement.
Simcere Pharmaceutical Group Limited has announced the acquisition of the entire assets of Sanroad Shanghai and the entire equity interest in Xianwei for a total cash consideration of RMB83,183,800. This strategic move will result in Xianwei becoming an indirectly wholly-owned subsidiary, with its financial results consolidated into Simcere’s financial statements, enhancing the company’s operational scope and market positioning.
More about Simcere Pharmaceutical Group Limited
Simcere Pharmaceutical Group Limited is a company incorporated in Hong Kong, operating within the pharmaceutical industry. It focuses on the acquisition and development of pharmaceutical assets and equity interests to enhance its market position.
Average Trading Volume: 21,796,197
Technical Sentiment Signal: Buy
Current Market Cap: HK$36.63B
For an in-depth examination of 2096 stock, go to TipRanks’ Overview page.